Muscles make up nearly 40% of the human body and power every move we make, from a child's first steps to recovery after ...

Revvity's Dharmacon All-in-one lentiviral platform has expanded to include whole-genome library options for CRISPR knockout (CRISPRko), CRISPR interference (CRISPRi), and CRISPR activation (CRISPRa).

In the world of biopharmaceutical innovation, 2024 will be remembered as CRISPR’s breakout year. In the spring, five patients with sickle cell disease began treatment with Casgevy, the first ...

Clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated (Cas) proteins are core components of fast-evolving therapeutic gene editing tools. Scientists have used CRISPR ...

CRISPR Therapeutics CRSP is currently the only company in the world to have secured approval for a CRISPR-based gene therapy developed in partnership with Vertex Pharmaceuticals. Following the ...

Shares of CRISPR Therapeutics CRSP have risen 14% over the past month, likely driven by encouraging results from the first candidates in its in vivo pipeline. CRSP’s Positive In Vivo Therapy Data Last ...

Out of the many challenges scientists face in bringing genomic medicine to patients, delivery is near the top of the list. Due to these barriers in getting the genetic payload to the correct target ...

Crispr Therapeutics (CRSP) is downgraded to "Hold" as current valuation already reflects optimism for CTX310 Phase I results and pipeline progress. Intellia Therapeutics (NTLA) maintains a "Buy" ...

Last month, CRSP reported initial top-line results from an early-stage study on CTX310, its investigational in vivo CRISPR-based gene therapy, designed to target ANGPTL3 for the treatment of ...